Vaxart, Inc. (OTC:VXRT)
| Market Cap | 118.99M+36.1% |
| Revenue (ttm) | 243.06M+201.1% |
| Net Income | 38.59M+168.1% |
| EPS | 0.15+155.5% |
| Shares Out | 242.84M |
| PE Ratio | 3.27 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Nov 9, 2012 |
| Volume | 23,972 |
| Open | 0.45 |
| Previous Close | 0.48 |
| Day's Range | 0.45 - 0.49 |
| 52-Week Range | 0.31 - 0.84 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | 2.00(+308.16%) |
| Earnings Date | Nov 12, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About VXRT
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
$VXRT stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in VXRT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VXRT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VXRT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VXRT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VXRT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VXRT
| ETF | Est. Holding Size |
|---|---|
| SILXETFMG Prime 2x Daily Junior Silver Miners ETF | $34.12K |
| VALTETFMG Sit Ultra Short ETF | $30.14K |
| GERMETFMG Treatments, Testing and Advancements ETF | $22.74K |
Estimated from each fund’s disclosed top holdings × AUM
VXRT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from VXRT’s recent data — informational, not investment advice